Trial shows immunotherapy drug Opdivo is safe, effective against Hodgkin lymphoma

The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, a new study shows.

Related Keywords

United States ,Chicago ,Illinois ,Boston ,Massachusetts ,Dana Farber Cancer Institute ,American ,Alex Herrera ,Oreofe Odejide ,Julie Gralow ,National Institutes Of Health ,American Society For Clinical Oncology ,American Cancer Society ,Bristol Myers Squibb ,American Society ,Clinical Oncology ,American Cancer ,Bristol Myers ,National Institutes ,Medical Officer ,North American ,Health ,